Dec 15, 2008 by Brian Orelli, PhDMedicine Gets a Little More PersonalBaby steps, however tiny, are still progress.
Dec 12, 2008 by Brian Orelli, PhDThe Skinny on the Latest Drug TrialVIVUS' data looks good, but will its drug be a marketing success?
Dec 12, 2008 by Brian Orelli, PhDAmylin Gets Some FDA LoveAmylin's once-weekly diabetes drug Byetta gets a green light from the FDA.
Dec 12, 2008 by Brian Orelli, PhDA Long-Term Play for Your PortLong-term prospects look better than the near term for Eli Lilly and its investors.
Dec 12, 2008 by Brian Orelli, PhDMartek Meanders Through the YearGrowth has slowed down, but it's still a good deal.
Dec 11, 2008 by Brian Orelli, PhDASH Wrap-Up: Alphabet Soup and DrugsBlood disorders are big business.
Dec 11, 2008 by Brian Orelli, PhDDrug Developers Want a Bailout, TooSeriously, who isn't angling for Federal cash now?
Dec 11, 2008 by Brian Orelli, PhDDrugmakers Could Lose Their Greatest WeaponCongress is thinking about putting limits on direct-to-consumer advertisements.
Dec 9, 2008 by Brian Orelli, PhDFDA Dashes Amylin Investors' Hopes Drug companies will have to wait for important decision on diabetes drug.
Dec 9, 2008 by Brian Orelli, PhDThe FDA Can't See the Forest or the TreesForest and Cypress are still waiting, but they've got more data to prove their point.
Dec 9, 2008 by Brian Orelli, PhDHuman Genome's Hep C Drug Is Halfway HomeOne trial down, one to go for Human Genome Sciences.
Dec 8, 2008 by Brian Orelli, PhDA Checkup for Makers of Asthma DrugsBecause of recent events, these companies face extra scrutiny from the FDA.
Dec 5, 2008 by Brian Orelli, PhDBe Kind to MannKindMannKind has good data, but will the FDA approve of it and will diabetics buy it?
Dec 5, 2008 by Brian Orelli, PhDMonsanto Ready to Round Up GrowthIt's hidden under the dirt for now, but it'll soon start sprouting.
